Trial Profile
A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO-040201 in Male and Female Subjects With Hypercholesterolemia
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ApoB SNALP (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Arbutus Biopharma
- 25 Nov 2014 New trial record